VCEL - Avita Medical: A Better Mousetrap With FDA Approval To Treat Patient Burns
There are many biotechnology companies that manage to gain the excitement of investors with the next revolutionary advancement in medicine. In reality, however, most of these companies are often a long, long way off to proving they will ever make it to an FDA authorized Phase III trial, much less commercialization. In fact, there are several billion-dollar market cap biotechs that come to mind that still haven't demonstrated safety. The CRISPR-Cas9 stock sector, the promising next big thing, is such an example. Editas Medicine Inc. (EDIT) and CRISPR Therapeutics AG (CRSP